Baxalta Gets FDA Approval for State-of-the-Art Singapore Facility

Baxalta announced that its state-of-the-art recombinant biologic manufacturing facility in Singapore received U.S. FDA approval to manufacture bulk drug substance for Advate, Baxalta’s market leading treatment for hemophilia A.
Source: PharmaManufacturing.com - Category: Pharmaceuticals Source Type: news